From consumer to tech, here's a list of key deals reported this week: Molson Coors Beverage (TAP) has agreed to acquire an 8.5% stake in Fevertree Drinks, becom ...
In its 10th year, SAGE opened its "My Hometown" photography show to anyone with a phone camera, stipulating any photo submitted needed to be taken and edited by phone.
Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...
Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on ...
New Jersey-based pharma and CPG insights firm BEESY has recruited James Arnold as a Research Director and brought Zoé Ziani ...
HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...
Learn more about whether Biogen Inc. or Natera, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Sage Therapeutics was in focus after it rejected Biogen's acquisition proposal. Sage Therapeutics stock gained after it announced that its board of directors has rejected the unsolicited, non-binding ...
Securities adjusted its outlook on Sage Therapeutics (NASDAQ:SAGE) shares, with analyst Vamil Divan increasing the price target to $9.00 from the previous $6.00, while maintaining a Neutral rating on ...
In a report released today, Uy Ear from Mizuho Securities maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report), with a price ...
While the strategic review process is underway, Sage Therapeutics continues to advance its mission of pioneering solutions to deliver life-changing brain health medicines. The company is committed to ...
Sage Therapeutics, Inc. filed an 8-K report with the Securities and Exchange Commission. The filing disclosed that the Board of Directors of Sage Therapeutics has commenced a strategic review process ...